• David H Birnie, Pablo B Nery, Andrew C Ha, and Rob S B Beanlands.
• Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada. Electronic address: dbirnie@ottawaheart.ca.
• J. Am. Coll. Cardiol. 2016 Jul 26; 68 (4): 411-21.

AbstractClinically manifest cardiac involvement occurs in perhaps 5% of patients with sarcoidosis. The 3 principal manifestations of cardiac sarcoidosis (CS) are conduction abnormalities, ventricular arrhythmias, and heart failure. An estimated 20% to 25% of patients with pulmonary/systemic sarcoidosis have asymptomatic cardiac involvement (clinically silent disease). In 2014, the first international guideline for the diagnosis and management of CS was published. In patients with clinically manifest CS, the extent of left ventricular dysfunction seems to be the most important predictor of prognosis. There is controversy in published reports as to the outcome of patients with clinically silent CS. Despite a paucity of data, immunosuppression therapy (primarily with corticosteroids) has been advocated for the treatment of clinically manifest CS. Device therapy, primarily with implantable cardioverter-defibrillators, is often recommended for patients with clinically manifest disease.Copyright © 2016 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

18 keywords...

hide…